medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-26-23-27medalphabet-2175Research ArticleСОВРЕМЕННАЯ ГИНЕКОЛОГИЯMODERN GYNECOLOGYВозможности КОК-ДРСП у женщин со стресс-зависимыми нарушениями менструального циклаPossibilities of COC-DRSP in women with stress-dependent menstrual irregularitieshttps://orcid.org/0000-0002-5520-281XХаджиеваН. Х.KhadzhievaN. Kh.

Хаджиева Нюржанна Хусеиновна, акушер-гинеколог

Москва

Khadzhieva Nyurzhanna Kh., obstetrician-gynecologist

Moscow

https://orcid.org/0000-0001-5541-3767КузнецоваИ. В.KuznetsovaI. V.

Кузнецова Ирина Всеволодовна, доктор медицинских наук, профессор, советник директора

Москва

Kuznetsova Irina V., DM Sci, professor, director’s advisor

Moscow

ЧУЗ «Центральная клиническая больница „РЖД-Медицина“»РоссияCentral Clinical Hospital ‘Russian Railways – Medicine’Russian FederationФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава РоссииРоссияNational Medical Research Centre for Obstetrics, Gynecology and Perinatology n.a. academician V.I. KulakovRussian Federation202124092021026Современная гинекология (2)2327Copyright © Хаджиева Н.Х., Кузнецова И.В., 20212021Хаджиева Н.Х., Кузнецова И.В.Khadzhieva N.K., Kuznetsova I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2175Цель исследования

Цель исследования. Оценка эффективности и безопасности КОК-ДРСП в контроле психосоматических симптомов у женщин со стрессзависимыми нарушениями менструального цикла.

Материалы и методы

Материалы и методы. В наблюдательном исследовании приняли участие 28 женщин в возрасте от 18 до 39 лет с соматоформным тревожным расстройством и нарушениями менструального цикла, появившимися в результате стрессовых событий и не имевшими тенденции к улучшению в процессе терапевтической модификации образа жизни и применения средств для улучшения адаптации. С целью предохранения от беременности и контроля менструального цикла пациенткам был назначен комбинированный оральный контрацептив, содержащий дроспиренон (ДРСП-КОК) в режиме «24 + 4». До начала исследования, через 3 и 6 месяцев после начала терапии оценивались психосоматические симптомы тревожного расстройства.

Результаты

Результаты. Прием ДРСП-КОК (Димиа) приводил к достоверному снижению частоты и выраженности психосоматических симптомов через три цикла терапии с сохранением эффекта при продолжении приема.

Заключение

Заключение. Прием ДРСП-КОК эффективен в облегчении психосоматических симптомов у женщин со стресс-зависимыми нарушениями менструального цикла.

Purpose of the study

Purpose of the study. Evaluation of the effectiveness and safety of COC-DRSP in the control of psychosomatic symptoms in women with stressdependent menstrual irregularities.

Materials and methods

Materials and methods. The observational study involved 28 women aged 18 to 39 years with somatoform anxiety disorder and menstrual irregularities resulting from stressful events and did not have a tendency to improve in the process of therapeutic lifestyle modification and the use of means to improve adaptation. In order to prevent pregnancy and control the menstrual cycle, the patients were prescribed a combined oral contraceptive containing drospirenone (DRSP-COC) in the «24 + 4» regimen. Prior to the study, 3 and 6 months after initiation of therapy, psychosomatic symptoms of anxiety disorder were assessed.

Results

Results. Reception of DRSP-COC (Dimia) led to a significant decrease in the frequency and severity of psychosomatic symptoms after three cycles of therapy with the preservation of the effect with continued administration.

Conclusion

Conclusion. DRSP-COC is effective in relieving psychosomatic symptoms in women with stress-related menstrual irregularities.

стрессменструальный циклолигоменореяпредменструальный синдромгипоталамическая дисфункциядроспиренонкомбинированные оральные контрацептивыstressmenstrual cycleoligomenorrheapremenstrual syndromehypothalamic dysfunctiondrospirenonecombined oral contraceptivesReferencesSharma R, Biedenharn KR, Fedor JM, Agarwal A. Lifestyle factors and reproductive health: taking control of your fertility. Reprod Biol Endocrinol. 2013; 11: 66. DOI: 10.1186/1477–7827–11–66.Sharma R, Biedenharn KR, Fedor JM, Agarwal A. Lifestyle factors and reproductive health: taking control of your fertility. Reprod Biol Endocrinol. 2013; 11: 66. DOI: 10.1186/1477–7827–11–66.Joseph DN, Whirledge S. Stress and the HPA Axis: Balancing Homeostasis and Fertility. Int J Mol Sci. 2017; 18 (10): 2224. DOI: 10.3390/ijms18102224.Joseph DN, Whirledge S. Stress and the HPA Axis: Balancing Homeostasis and Fertility. Int J Mol Sci. 2017; 18 (10): 2224. DOI: 10.3390/ijms18102224.Lucassen PJ, Pruessner J, Sousa N, Almeida OF, Van Dam AM, Rajkowska G, et al. Neuropathology of stress. Acta Neuropathol. 2014; 127 (1): 109–35. DOI: 10.1007/s00401–013–1223–5.Lucassen PJ, Pruessner J, Sousa N, Almeida OF, Van Dam AM, Rajkowska G, et al. Neuropathology of stress. Acta Neuropathol. 2014; 127 (1): 109–35. DOI: 10.1007/s00401–013–1223–5.Стеняева Н. Н., Хритинин Д. Ф., Григорьев В. Ю., Куземин А. А. Половые стероиды и функции головного мозга. Гинекология. 2017; 19 (2): 9–14.Stenyaeva N.N., Khritinin D. F., Grigoriev V. Yu., Kuzemin A.A. Sex steroids and brain function. Gynecology. 2017; 19 (2): 9–14.Goel N, Workman JL, Lee TT, Innala L, Viau V. Sex differences in the HPA axis. Compr Physiol. 2014 Jul; 4 (3): 1121–55. DOI: 10.1002/cphy.c130054. PMID: 24944032.Goel N, Workman JL, Lee TT, Innala L, Viau V. Sex differences in the HPA axis. Compr Physiol. 2014 Jul; 4 (3): 1121–55. DOI: 10.1002/cphy.c130054. PMID: 24944032.Labombarda F, Garcia-Ovejero D. Give progesterone a chance. Neural Regen Res 2014; 9 (15): 1422–4. DOI: 10.4103/1673–5374.139456.Labombarda F, Garcia-Ovejero D. Give progesterone a chance. Neural Regen Res 2014; 9 (15): 1422–4. DOI: 10.4103/1673–5374.139456.Кубасов Р.В., Барачевский Ю.Е., Лупачев В.В. Функциональные изменения гипофизарно-гонадного и тиреоидного эндокринных звеньев в ответ на стрессовые факторы. Фундаментальные исследования. 2014; 10: 1010–1014.Kubasov R. V., Barachevsky Yu.E., Lupachev V. V. Functional changes in the pituitary-gonadal and thyroid endocrine links in response to stress factors. Basic research. 2014; 10: 1010–1014.Toufexis D, Rivarola MA, Lara H, Viau V. Stress and the reproductive axis. J Neuroendocrinol. 2014; 26 (9): 573–586. DOI: 10.1111/jne.12179.Toufexis D, Rivarola MA, Lara H, Viau V. Stress and the reproductive axis. J Neuroendocrinol. 2014; 26 (9): 573–586. DOI: 10.1111/jne.12179.Valsamakis G, Chrousos G, Mastorakos G. Stress, female reproduction and pregnancy. Psychoneuroendocrinology. 2019; 2 (100): 48–57 DOI: 10.1016/j.psyneuen.2018.09.031.Valsamakis G, Chrousos G, Mastorakos G. Stress, female reproduction and pregnancy. Psychoneuroendocrinology. 2019; 2 (100): 48–57 DOI: 10.1016/j.psyneuen.2018.09.031.Dome P, Tombor L, Lazary J, Gonda X, Rihmer Z. Natural health products, dietary minerals and over-the-counter medications as add-on therapies to antidepressants in the treatment of major depressive disorder: a review. Brain Res Bull. 2019; 146: 51–78. DOI: 10.1016/j.brainresbull.2018.12.015.Dome P, Tombor L, Lazary J, Gonda X, Rihmer Z. Natural health products, dietary minerals and over-the-counter medications as add-on therapies to antidepressants in the treatment of major depressive disorder: a review. Brain Res Bull. 2019; 146: 51–78. DOI: 10.1016/j.brainresbull.2018.12.015.Pattanittum P, Kunyanone N, Brown J, Sangkomkamhang US, Barnes J, Seyfoddin V, Marjoribanks J. Dietary supplements for dysmenorrhoea. Cochrane Database Syst Rev. 2016; 3 (3): CD002124. DOI: 10.1002/14651858.CD002124.pub2.Pattanittum P, Kunyanone N, Brown J, Sangkomkamhang US, Barnes J, Seyfoddin V, Marjoribanks J. Dietary supplements for dysmenorrhoea. Cochrane Database Syst Rev. 2016; 3 (3): CD002124. DOI: 10.1002/14651858.CD002124.pub2.McCabe D. The impact of essential fatty acid, B vitamins, vitamin C, magnesium and zinc supplementation on stress levels in women: a systematic review. JBI Database System Rev Implement Rep, 2017 DOI: 10.11124/JBISRIR2016–002965.McCabe D. The impact of essential fatty acid, B vitamins, vitamin C, magnesium and zinc supplementation on stress levels in women: a systematic review. JBI Database System Rev Implement Rep, 2017 DOI: 10.11124/JBISRIR2016–002965.Громова О.А., Торшин И.Ю., Тетруашвили Н.К. Использование рибофлавина и цитрата магния в акушерстве и гинекологии. Гинекология. 2018; 20 (6): 60–66. doi.org/10.18565/aig.2018.1.21–28Gromova O.A., Torshin I. Yu., Tetruashvili N.K. The use of riboflavin and magnesium citrate in obstetrics and gynecology. Gynecology. 2018; 20 (6): 60–66.Caumo W, Hidalgo MP, Souza A, Torres ILS, Antunes LC. Melatonin is a biomarker of circadian dysregulation and is correlated with major depression and fibromyalgia symptom severity. J Pain Res. 2019; 12: 545–556. DOI: 10.2147/JPR.S176857.Caumo W, Hidalgo MP, Souza A, Torres ILS, Antunes LC. Melatonin is a biomarker of circadian dysregulation and is correlated with major depression and fibromyalgia symptom severity. J Pain Res. 2019; 12: 545–556. DOI: 10.2147/JPR.S176857.Giribela CR, Consolim-Colombo FM, Nisenbaum MG. Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women. Gynecol Endocrinol. 2015; 31 (11): 912–915 DOI: 10.3109/09513590.2015.1062860.Giribela CR, Consolim-Colombo FM, Nisenbaum MG. Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women. Gynecol Endocrinol. 2015; 31 (11): 912–915 DOI: 10.3109/09513590.2015.1062860.Machado RB, Pompei Lde M, Giribela AG, Giribela CG. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits. Womens Health (Lond). 2011; 7 (1): 19–30. DOI: 10.2217/whe.10.84.Machado RB, Pompei Lde M, Giribela AG, Giribela CG. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits. Womens Health (Lond). 2011; 7 (1): 19–30. DOI: 10.2217/whe.10.84.Твердикова М. А., Гависова А. А. Дроспиренон – надежная контрацепция и неконтрацептивные эффекты. РМЖ. 2012; 1: 1–5.Tverdikova M.A., Gavisova A.A. Drospirenone is a reliable contraception and non-contraceptive effects. Breast cancer. 2012; 1: 1–5.Кузнецова И. В., Коновалов В. А. Нарушения менструального цикла и их гормональная коррекция в контексте стресс-зависимых психовегетативных расстройств. Медицинский совет. 2014; 9: 12–16 DOI: 10.21518/2079–701X2014–9–12–16.Kuznetsova I.V., Konovalov V.A. Menstrual irregularities and their hormonal correction in the context of stress-dependent psycho-vegetative disorders. Medical Advice. 2014; 9: 12–16. DOI: 10.21518/2079–701X2014–9–12–16.Takimoto-Ohnishi E, Murakami K. Renin-angiotensin system research: from molecules to the whole body. J Physiol Sci. 2019; 69 (4): 581–587. DOI: 10.1007/s12576–019–00679–4.Takimoto-Ohnishi E, Murakami K. Renin-angiotensin system research: from molecules to the whole body. J Physiol Sci. 2019; 69 (4): 581–587. DOI: 10.1007/s12576–019–00679–4.Унанян А.Л., Сидорова И.С., Кузенкова Н.Н. Предменструальный синдром: этиопатогенез, классификация, клиника, диагностика и лечение. РМЖ. Мать и дитя. 2018; 2 (1): 34–38.Unanyan A. L., Sidorova I. S., Kuzenkova N.N. Premenstrual syndrome: etiopathogenesis, classification, clinical picture, diagnosis and treatment. Breast cancer. Mother and Child. 2018; 2 (1): 34–38.Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012; (2): CD006586. DOI: 10.1002/14651858.CD006586.pub4.Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012; (2): CD006586. DOI: 10.1002/14651858.CD006586.pub4.Lundin C, Danielsson KG, Bixo M, Moby L, Bengtsdotter H, Jawad I, et al. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double-blind, placebo-controlled randomized trial. Psychoneuroendocrinology. 2017; 76: 135–143. DOI: 10.1016/j.psyneuen.2016.11.033.Lundin C, Danielsson KG, Bixo M, Moby L, Bengtsdotter H, Jawad I, et al. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double-blind, placebo-controlled randomized trial. Psychoneuroendocrinology. 2017; 76: 135–143. DOI: 10.1016/j.psyneuen.2016.11.033.Gordon CM, Ackerman KE, Berga SL, Kaplan JR, Mastorakos G, Misra M, et al. Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017; 102 (5): 1413–1439. DOI: 10.1210/jc.2017–00131.Gordon CM, Ackerman KE, Berga SL, Kaplan JR, Mastorakos G, Misra M, et al. Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017; 102 (5): 1413–1439. DOI: 10.1210/jc.2017–00131.

The authors declare that there are no conflicts of interest present.